Year All20242023202220212020 September 5, 2024 Invivyd to Participate in Upcoming Investor Conferences September 4, 2024 Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ September 3, 2024 Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest August 27, 2024 Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial August 14, 2024 Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 12, 2024 Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights July 1, 2024 Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes June 14, 2024 Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants June 3, 2024 Invivyd to Participate at the Jefferies Global Healthcare Conference May 31, 2024 Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
